Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 282
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
atai Life Sciences AG Announces Equity Investment in and Strategic Partnership...
Psychedelic Capitalism and Other Myths: Is the Joke On Us?
Psychotic- vs. Psychedelic-Induced Hallucinations: A Closer Look
Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering
Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal...
Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces...
Psyched Wellness Submits a Provisional Patent Application For AME-1
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug...
Optimi Health Receives Health Canada NPN Product Licenses in Preparation for...
World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific...
Load more